A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)
This study is testing a new, experimental medication called BH-30643 to see how well it works against advanced lung cancer. It is specifically designed for patients whose tumors have certain genetic changes, known as EGFR or HER2 mutations.
You may be eligible if you are at least 18 years old and have advanced lung cancer with confirmed EGFR or HER2 mutations. Participants must also be active enough to manage daily tasks and have measurable tumors outside of the brain.
In the first part of the study, researchers will find the safest and most effective dose of the new drug, sometimes combined with standard chemotherapy. In the second part, they will watch closely to see how well the treatment shrinks tumors and how patients feel while taking it.
The study is currently recruiting volunteers at medical centers in Phoenix, Arizona, as well as Irvine and La Jolla, California. Your medical team will provide more specific details on the timeline if you qualify.
- 1This is an early-stage study testing a new treatment approach for specific types of lung cancer.
- 2Participants will be closely monitored by medical professionals to ensure safety and track the drug’s effectiveness.
- 3The goal is to find better treatment options for patients whose lung cancer has specific genetic mutations.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.